Tag Archives: pricing and reimbursement

Managing High-Priced, US Biotech Rxs in Canada

As the “Saga of Sovaldi” continues to unfold in the U.S., and Congress, insurers, providers, and the U.S. Rx manufacturer, Gilead, hurl charges back and forth at each other, it’s pretty clear the situation will only continue to deteriorate. However, as you look north of the American border, it’s striking how Canadian healthcare entities are managing […]
Posted in Op-Ed, pricing | Also tagged , , , | Leave a comment

Innovation Drops Down NICE’s Value Agenda

Innovation as a consideration of value-based pricing decisions will be conspicuous by its absence in future NICE decisions. Omar Ali, a UK formulary development pharmacist and consultant to NICE, speaking at eyeforpharma’s Barcelona 2014 conference on Wednesday, explained that the UK price watchdog will prioritize considerations of wider societal benefit and unmet need as it […]
Posted in Europe, Events, pricing | Also tagged , , , , | Leave a comment

Europe: Whatever Happened to Faster Reimbursement for Generics?

The plan to accelerate generic pricing and reimbursement has become another tragic European casualty, writes Brussels correspondent Reflector.
Posted in Europe, Op-Ed, pricing, Regulatory | Also tagged , , , , | Leave a comment

FDA Guidances, OIG Investigations to Shape Drug Marketing, Research

Marketers may see further advice from the Food and Drug Administration in the coming year that clarifies how they can use social media. Priority topics:  presenting risk and benefit information in limited space; correcting independent/third party misinformation about a drug or medical device; and appropriate use of links, according to the agenda for the Center […]
Posted in Advertising, Biotech, E-Media, FDA, Legal, pricing, Regulatory, social media | Also tagged , , , , , , | Leave a comment

$20 Billion 'Lifestyle' Market Immune to Costly Regulations, says Alphaeon CEO

You can’t defraud the government if you aren’t handling its money, explains Robert Grant, CEO of Alphaeon, a lifestyle healthcare company. Pharma free-market advocates take note. If you no longer had to worry about the Anti-Kickback Statute, Stark Law or the Sunshine Act, would your professional marketing strategy change? Probably, if you like making money. […]
Posted in FDA, Global, Legal, Market Access, People, pricing, R&D, Regulatory, social media, Strategy, Technology | Also tagged , , , , , , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta